Enteric infections and the vaccines to counter them: future directions (Q36444089)

14 August 2017

1 reference

title

Enteric infections and the vaccines to counter them: future directions (English)

1 reference

14 August 2017

1

Myron M Levine

1 reference

PubMed ID

16603279

14 August 2017

language of work or name

English

0 references

publication date

24 March 2006

1 reference

14 August 2017

9

1 reference

inferred from page(s)

published in

Vaccine

1 reference

14 August 2017

24

1 reference

14 August 2017

18

1 reference

14 August 2017

3865-3873

1 reference

Overview of vaccines and immunisation

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Vaccines against Campylobacter jejuni

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Genetically engineered enteropathogenic Escherichia coli strain elicits a specific immune response and protects against a virulent challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Opportunities and obstacles in developing a vaccine for Entamoeba histolytica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Prevention of intestinal amebiasis by vaccination with the Entamoeba histolytica Gal/GalNac lectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Present and future control of cryptosporidiosis in humans and animals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

The humoral and cellular immune responses in mice induced by DNA vaccine expressing the sporozoite surface protein of Cryptosporidium parvum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Effectiveness of mass oral cholera vaccination in Beira, Mozambique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Live oral cholera vaccine : from principle to product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Can oral cholera vaccination play a role in controlling a cholera outbreak?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Persistent Efficacy of Vi Conjugate Vaccine against Typhoid Fever in Young Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Shigella dysenteriae serotype 1 in west Africa: intervention strategy for an outbreak in Sierra Leone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Epidemic Shiga Bacillus Dysentery in Central America. I. Etiologic Investigations in Guatemala, 1969

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18–36 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Construction and characterization of genetically defined aro omp mutants of enterotoxigenic Escherichia coli and preliminary studies of safety and immunogenicity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Concurrent oral poliovirus and rhesus-human reassortant rotavirus vaccination: effects on immune responses to both vaccines and on efficacy of rotavirus vaccines. The US Rotavirus Vaccine Efficacy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Oral polio vaccination of children in the tropics. III. Intercurrent enterovirus infections, vaccine virus take and antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Oral polio vaccination of children in the tropics. II. Antibody response in relation to vaccine virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Safety, Immunogenicity, and Protective Efficacy of One and Three Doses of the Tetravalent Rhesus Rotavirus Vaccine in Infants in Lima, Peru

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Stabilisation of Salmonella vaccine vectors by the induction of trehalose biosynthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

Preliminary assessment of the safety and immunogenicity of a new CTXPhi-negative, hemagglutinin/protease-defective El Tor strain as a cholera vaccine candidate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

7 January 2021

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

7 January 2021

Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

7 January 2021

Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

7 January 2021

Biotechnological applications of the disaccharide trehalose.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.039

7 January 2021

10.1016/J.VACCINE.2006.03.039

Identifiers

DOI

1 reference

release_tk7gsuroajgp5dvc62drgkhgue

14 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tk7gsuroajgp5dvc62drgkhgue

24 November 2022

mapped directly with Wikidata item

PubMed ID

16603279

1 reference

PubMed ID

16603279